Background. Patients with pulpal and periapical conditions often seek treatment for pain, intraoral swelling, or both. Even when definitive, conservative dental treatment (DCDT) is an option, antibiotics are often prescribed. The purpose of this review was to summarize available evidence regarding the effect of antibiotics, either alone or as adjuncts to DCDT, to treat immunocompetent adults with pulpal and periapical conditions, as well as additional population-level harms associated with antibiotic use.
colleagues 1 reported in 2015 that among a sample of 1,688 adult dental patients, 9% reported dentoalveolar pain during the past 12 months. Sometimes, patients cannot access a dentist when they experience symptoms and seek out emergency care in nondental settings. From 2011 through 2015, more than 400,000 patients treated in US hospital emergency departments (EDs) had diagnostic codes related to pulpal and periapical conditions, which accounted for 19% of all ED visits associated with a dental diagnosis. 2 In 2015, diseases of the teeth and gingiva were among the top 20 reasons for any ED visit in patients aged 15 through 64 years. 3 Dental pain associated with pulpal and periapical conditions usually results from caries. As caries progresses into the pulp, the patient can develop reversible pulpitis, in which the pulp becomes inflamed causing either stimulated (for example, response to cold) or unstimulated (for example, spontaneous) pain. If the pulp is incapable of healing and the patient experiences lingering or spontaneous pain with thermal changes, this is known as symptomatic irreversible pulpitis (SIP). Once the inflammation spreads beyond the canal system and into the periodontal ligament space around the root, the patient will experience pain with mastication, percussion, or palpation, with or without evidence of radiographic periapical pathosis, referred to as symptomatic apical periodontitis (SAP). If the pulp does not respond to pulp testing, this is usually a sign that pulp vitality is compromised irreversibly (pulp necrosis). If necrotic pulp is not treated endodontically, it may become infected, and the patient can develop a localized acute apical abscess (LAAA) with formation of purulent material and localized swelling. 4, 5 If the abscess is left untreated, the infection may spread into adjacent fascial space or local lymph nodes, and the patient may seek treatment for systemic involvement (for example, fever, chills, malaise, or cellulitis) ( Table 1) . 5 Definitive, conservative dental treatment (DCDT), or tooth-preserving treatments, includes a range of effective strategies to manage the pulpal and periapical conditions described above. DCDT cannot always be provided immediately, and antibiotics are prescribed frequently as an attempt to temporarily manage distressing patient symptoms such as pain and intraoral swelling. From 2011 through 2015, antibiotics were prescribed in 85% of ED visits for pulpal and periapical conditions. 2 Antibiotics may be necessary for some patients, and although there is published literature on appropriate versus inappropriate antibiotic types and regimen durations used in dentistry, to our knowledge, no comprehensive guidance exists for United States general dental practitioners on when it may be appropriate versus inappropriate to prescribe antibiotics for pulpal and periapical conditions. [6] [7] [8] [9] It is also important to note that although antibiotics can be life-saving drugs, their use, whether inappropriate or appropriate, can result in unintended consequences including antibiotic resistance and adverse patient outcomes. 10, 11 The purpose of this review is to present evidence on the effect of antibiotic therapy compared with no antibiotic therapy, used alone or as adjuncts to DCDT for the treatment of SIP with or without SAP, pulp necrosis and symptomatic apical periodontitis (PN-SAP), or pulp necrosis and localized acute apical abscess (PN-LAAA) in immunocompetent patients (that is, patients with the ability to mount a bacterial challenge). This review was developed by methodologists at the American Dental Association (ADA) Center for Evidence-Based Dentistry and a multidisciplinary Table 1 . Pulpal and periapical target conditions and their clinical signs and symptoms.
TARGET CONDITION CHARACTERISTICS OF CLINICAL SIGNS AND SYMPTOMS Symptomatic Irreversible Pulpitis
Spontaneous pain that may linger with thermal changes owing to vital inflamed pulp that is incapable of healing group of subject matter experts convened by the ADA Council on Scientific Affairs. Its content informed the development of a clinical practice guideline on the appropriate use of antibiotics for the urgent management of pulpal-and periapical-related pain and intraoral swelling published in The Journal of the American Dental Association. 12 
METHODS
The Cochrane Collaboration published systematic reviews in 2014 and 2016 on the effects of systemic antibiotics for SAP and LAAA and for SIP in immunocompetent adults, respectively. 13, 14 We chose to update and integrate both Cochrane reviews as part of our review and followed guidance from the Preferred Reporting Items of Systematic Reviews and Meta-Analyses 15 checklist to write this article.
Selection criteria
For the update of the Cochrane reviews, 13, 14 we adhered to the selection criteria described below. Studies identified from Cope and colleagues, 13 review, (n = 2)
Records identified through search strategy 1 (n = 408) Studies included in qualitative and quantitative synthesis (n = 3)
Records screened after duplicates removed (n = 624) Titles and abstracts excluded (n = 578)
Duplicates removed (n = 90)
Duplicates removed (n = 91)
Records identified through search strategy 2 (n = 401) Full text articles assessed for eligibility (n = 46)
Studies included from updating process (n = 0)
Full text articles excluded, with reasons (n = 46) Figure 1 . Preferred Reporting Items for Systematic Reviews and Meta-Analyses 15 flowchart of the screening and study-selection process for randomized controlled trials.
Type of Studies
Randomized controlled trials (RCTs) with any follow-up time.
Participants
Immunocompetent adults 18 years of age or older, with SIP with or without SAP, PN-SAP, or PN-LAAA, with no other comorbidities. Immunocompromised patients were excluded. Reporting in the study did not allow for ascertaining of the timing of the initiation of antibiotic therapy in relation to definitive, conservative dental treatment. No assessment of adverse effects to either the antibiotics or analgesics were reported by the investigators.
Records identified through search strategy 3 (n = 3,031) (antibiotic resistance)
Additional records identified through other sources (n = 8)
Records screened after duplicates removed (n = 2,430) Titles and abstracts excluded (n = 2,421)
Full-text articles assessed for eligibility (n = 9)
Full-text articles excluded, with reasons (n = 9)
Studies included in qualitative synthesis (n = 8)
Studies included in quantitative synthesis
(meta-analysis) (n = 0) Figure 2 . Preferred Reporting Items for Systematic Reviews and Meta-Analyses 15 flowchart of the screening and studyselection process for systematic reviews.
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Intervention and Comparison
Administration of any oral systemic antibiotic at any dosage compared with no antibiotic administration, with or without any analgesics at any dosage, with or without DCDT immediately available. DCDT refers to pulpectomy, pulpotomy, nonsurgical root canal treatment, or incision and drainage. Extractions are not considered conservative management (that is, the goal of treatment is to preserve the tooth) and hence were excluded from the scope of this review.
Outcomes
Pain, intraoral swelling, total number of analgesics used, progression of the disease to a more severe state, allergic reactions, and adverse events, including endodontic flare-up, diarrhea, Clostridioides difficile infection (CDI), and repeat procedure. A full listing of outcomes is in the appendix, available at the end of this article.
Additional selection criteria
Anticipating paucity of evidence from RCTs informing harm or undesirable outcomes, we defined additional criteria to expand our review and include observational data. We used the selection criteria described below.
Type of Studies
Systematic reviews of observational studies, defined as explicit reporting of a systematic search including at least 2 databases, published within the past 5 years. We also retrieved individual observational studies, with no date limit, from key health care and government agencies monitoring harms related to antibiotic use. We prioritized studies reporting U.S. national estimates over singlecenter studies.
Participants
Any person of any age seeking treatment in any dental setting in the United States. If data directly collected from dental settings were not available, we prioritized available data in the following order: n patients seeking treatment in any outpatient setting in the United States; n patients seeking treatment in any health care setting in the United States (for example, hospital or long-term care facility).
Exposures
Patients receiving any systemic antibiotic for the management of any health condition, including the conditions of interest. When the studies included populations of both patients exposed and not exposed to antibiotics, we prioritized the inclusion of those who received antibiotics. When unable to distinguish these 2 populations, we included the study and acknowledged this limitation. Outcomes Any harm or undesirable outcome, including but not limited to community-associated CDI, antibiotic-resistant infections, costs, hospitalizations, and anaphylaxis. A full listing of outcomes is in the Appendix, available at the end of this article.
Literature search
In conjunction with the expert panel and methodologists, an informationist (K.K.O.) developed an inclusive search strategy consisting of 3 components: n an update of the 2013 Cochrane review by Cope and colleagues 13 ; n an update of the 2016 Cochrane review by Agnihotry and colleagues 14 ; n a search for systematic reviews on outcomes of harm (undesireable effects) related to antibiotic use. The published search strategy for the Cope and colleagues 13 review was translated into and replicated in all databases being used for this search (search strategy 1 in the Appendix, available at the end of this article). The published search strategy for the Agnihotry and colleagues 14 review was adapted for inclusivity by means of combining the antibiotics search string used in the Cope and colleagues review 13 with a new, simple pulpectomy and dental pulp concept (search strategy 2 in the Appendix). Database-supplied publication date limits were used to limit from the date of last update onward for both systematic reviews. The informationist used the clinical queries filter to limit to systematic reviews in PubMed, 22 and the SIGN filter 23 was used to limit to systematic reviews in all other databases for the search for systematic reviews on outcomes of harms related to antibiotic use (search strategy 3 in the Appendix). To limit to adult humans, the informationist used filters based on the model outlined in the Cochrane Handbook for Systematic Reviews of Interventions, chapter 6.4.11. 24 Database-supplied limits were applied to restrict to items published within the past 5 years.
We ran all 3 searches in 4 databases: MEDLINE via PubMed, Embase via embase.com, the Cochrane Library 2018, issue 6; and the Cumulative Index to Nursing and Allied Health Literature Complete via EBSCO. We also searched the gray literature (World Health Organization International Clinical Trials Registry Platform, ClinicalTrials.gov, and OpenGrey). We did not apply any restriction on language to any of the searches. In addition, we searched health care and government agencies Web sites and databases and contacted the panel representative, Michele Neuburger, from the Centers for Disease Control and Prevention for additional information on published resources. All searches were completed in late May and early June 2018. In September 2019, and before we submitted this manuscript for publication, we updated the search strategies for MEDLINE via PubMed.
Selection of primary studies and data extraction
The authors of this review independently and in duplicate conducted title and abstract screening of references retrieved from the 3 search strategies: Table 2 shows the excluded studies).
Pairs of reviewers (L.P., M.P.T., O.U.) independently extracted outcome data from the relevant studies using standardized forms. Abstracted study characteristics from reports included country, study design, patient characteristics, follow-up time, intervention characteristics, description of included study population, observation and data collection period, methods, conflicts of interest, and funding source. We contacted primary study authors when clarification was needed.
Outcome measures
We analyzed pain as continuous outcomes and dichotomized ordinal scales and analyzed intraoral swelling as dichotomized ordinal scales (Appendix, available at the end of this article).
We presented dichotomous outcomes using relative risks and continuous outcomes using mean differences, both accompanied by their 95% confidence intervals (Appendix). For beneficial e192 outcomes, we calculated absolute measures for all relative measures using baseline risks (control group risk). For harm outcomes, we presented data using a common denominator of 10,000 or 100,000 for ease of comparison between outcomes, if possible.
Statistical analysis
We conducted meta-analysis using a random-effects model to obtain pooled estimates using Review Manager, Version 5.3 (Cochrane Collaboration). When meta-analysis was not possible (for example, owing to population differences between studies), we attempted to calculate and report relative risks and mean differences at an individual study level. When data directly informing the impact of antibiotic prescriptions in dentistry were not available, we calculated both the overall estimate for all prescriptions in the health care system and illustrated the potential impact of antibiotics prescribed by dentists via attributing 10% of the burden of harm outcomes to dental prescriptions. This was based on estimations that suggest that dentistry accounts for approximately Was the study's target population a close representation of the population in relation to relevant variables?
Was the sampling frame a true or close representation of the target population?
Was some form of random selection used to select the sample, or was a census undertaken?
Was the likelihood of nonresponse bias minimal?
Were data collected directly from the participants (as opposed to a proxy)?
Was an acceptable case definition used in the study?
Was the study method that measured the outcome(s) shown to have validity and reliability?
Was the mode of data collection used for all subjects?
Was the length of the shortest prevalence period for the parameter of interest appropriate?
Were the numerator(s) and denominator(s) for the parameter of interest appropriate and clearly reported?
= No report available = Yes = No
Dhopeshwarkar and colleagues, 28 2019
Chitnis and colleagues, 27 2013 Centers for Disease Control and Prevention, 11 2013
Hicks and colleagues, 26 2015
Johnston and colleagues, 29 2019 Lessa and colleagues, 30 one-tenth of total outpatient antibiotic prescriptions by all providers in the United States (third highest prescribers among all health care specialties). 8, 25, 26 We also calculated the national CDI burden estimates to specify burden of CDIs and hospitalizations that are community associated and, if possible, community-associated CDIs attributable to antibiotic prescribing and consumption; we adjusted our analysis considering that 64% of community-associated CDIs are associated with antibiotic consumption and that 12% of community-associated CDIs are the primary reason for hospital admissions. 27 Assessment of risk of bias and methodological quality Two pairs of reviewers (L.P., M.P.T., O.U.) independently assessed the risk of bias of the included studies and the quality of any preexisting reviews, using the Cochrane Risk of Bias tool, Hoy and Table 5 . Relative and absolute desirable and undesirable effects (95% confidence interval) from randomized controlled trials and certainty in the evidence for systemic antibiotics compared with no systemic antibiotics for symptomatic irreversible pulpitis with or without symptomatic apical periodontitis in immunocompetent adults when definitive, conservative dental treatment is not available. * Selection criteria: patient or population: immunocompetent adults with symptomatic irreversible pulpitis with or without symptomatic apical periodontitis; setting: dental settings in which definitive, conservative dental treatment is not immediately available; intervention: systemic antibiotics; comparison: no systemic antibiotic. No studies meeting the selection criteria reported data on malaise, trismus, fever, cellulitis, additional dental visit, additional medical visit, allergic reaction, endodontic flare-up, diarrhea, Clostridioides difficile infection, or repeat procedure for this population. Nagle and colleagues 18 did report intraoral swelling, but owing to symptom inconsistencies with a clinical diagnosis of symptomatic irreversible pulpitis with or without symptomatic apical periodontitis, the guideline authors did not extract this data. † GRADE: Grading of Recommendations Assessment, Development and Evaluation. GRADE Working Group grades of evidence: high certainty: we are very confident that the true effect lies close to that of the estimate of the effect; moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. ‡ RR: Risk ratio. § For dichotomous outcomes, the guideline authors calculated absolute treatment effects via using the control group's baseline risk as the assumed control intervention risk. { RCT: Randomized controlled trial. # Nagle and colleagues. 18 ** Serious issues of imprecision due to small sample size. † † MD: Mean difference. ‡ ‡ There were serious issues of imprecision due to small sample size, and the confidence interval suggests a large benefit and a large harm. § § For Nagle and colleagues, 18 the data for the outcome of pain were dichotomized (visual analog scale from 0-3) as follows: "no pain" and "mild pain" were coded as "no pain," and "moderate pain" and "severe pain" were coded as "pain." {{ There were serious issues of imprecision due to small sample size, and the confidence interval suggests both a small benefit and a large harm.
OUTCOMES
colleagues, 19 and AMSTAR 2 appraisal tool. 20 Any disagreements in judgments were resolved by a third reviewer (A.C.-L.) (Appendix, available at the end of this article).
Certainty in the evidence
We assessed the certainty in the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach across studies at an outcome level (Appendix, available at the end of this article). 21 
RESULTS

Characteristics of included studies
We used the reviews by Agnihotry and colleagues 14 and Cope and colleagues 13 containing 3 RCTs to inform benefits and harms of antibiotic use for the target conditions. In our search to update both reviews, 13, 14 we screened 628 titles and abstracts and 46 citations for full-text screening and found no studies meeting our selection criteria ( Figure 1 ). These 3 RCTs were conducted in the United States and included adult patients seeking emergency treatment of the target conditions (number of patients who completed the trials, 111) ( Table 3) . [16] [17] [18] Patients in the intervention groups received antibiotics with or without DCDT, whereas those in the control groups received either no antibiotics or placebo, with or without DCDT. Patients in both intervention and control groups received analgesics (ibuprofen) with or without rescue analgesics (acetaminophen plus codeine), as well as written and verbal instructions for the management of pain. To collect additional harm outcome data not available through RCTs, we screened 2,430 titles and abstracts from search strategy 3 (Appendix, available at the end of this article) and selected 9 reports for full-text screening; ultimately, none were included. We found 8 individual reports through searching in health care and government agencies databases and resources ( Figure 2 ). 11, [26] [27] [28] [29] [30] [31] [32] These studies, published between 2011 and 2019, were all conducted in the United States and used either a cross-sectional, active population and laboratory-based surveillance, or systematic review methodology to obtain their results (Table 4) . 11, [26] [27] [28] [29] [30] [31] [32] Risk of bias and methodological quality assessment For the included RCTs, a full risk of bias assessment was not possible because reporting issues forced unclear judgments for selective reporting and incomplete outcome data. We determined that the domain of incomplete outcome data was the most serious methodological concern among the 3 studies ( Figure 3 ). [16] [17] [18] For the observational reports informing additional harm or undesirable outcomes, 1 systematic review 32 was judged to be of poor methodological quality and 6 individual studies [26] [27] [28] [29] [30] [31] were judged as at low risk of bias. For the systematic review, 32 the most serious methodological concerns were lack of a protocol, limited risk of bias assessment, and limited information on meta-analytical methods. For the 6 remaining reports, [26] [27] [28] [29] [30] [31] random sample selection did not occur among most of the included studies. A full risk of bias assessment was not possible for 1 study 11 owing to poor reporting and, therefore, we were unable to assess most of the risk of bias domains (Figure 4 ). [26] [27] [28] [29] [30] [31] 
FAVORS NO ANTIBIOTIC FAVORS ANTIOBIOTIC
Effects of interventions No DCDT Available: Oral Systemic Antibiotics Compared With the Nonuse of Oral Systemic Antibiotics
SIP with or without SAP One study (N ¼ 40, 7-day follow-up) informed the effect of antibiotics for improving the following beneficial outcomes in immunocompetent adults with SIP with or without SAP. 18 We located data for all outcomes except endodontic flare-up, diarrhea, CDI, allergic reaction, repeat procedure, and progression of disease to a more severe state such as malaise and trismus (Appendix, available at the end of this article) for this population. The study authors did report intraoral swelling, but owing to e196 symptom inconsistencies with a clinical diagnosis of SIP with or without SAP, we disregarded these data ( Table 1) . 18 Patient-reported pain intensity and experience When receiving antibiotics, patients may experience differences of less than one-half a point on a visual analog scale (VAS) of pain, ranging from 0 through 3, compared with patients who did not receive antibiotics over 7 days (24, 48, and 72 hours and 7 days) (low certainty) ( Table 5 ; Figures 5-8 ). 18 Patients who received antibiotics may experience an increased risk of experiencing pain at 24 hours (20% increase) and 48 hours (22% increase), whereas no difference and a reduction (11% reduction) in pain were observed at 72 hours and 7 days follow-up, respectively, compared with patients who did not receive antibiotics (low certainty) ( 
Analgesic use
Patients who received antibiotics may use, on average, one-half of a 600 milligram ibuprofen tablet less and 2 more 300 mg tablets of acetaminophen with 30 mg of codeine rescue analgesic tablets over 7 days compared with patients who did not receive antibiotics (low certainty) ( Table 5 ; Figures 13-15 ). 18 For all of these outcomes, the described differences were not statistically significant. For the outcomes of patient-reported pain intensity and total analgesics used, these differences were also not clinically significant.
Pulp necrosis and SAP or LAAA
No studies met our selection criteria. Test for overall effect: z = 0.00 (P = 1.00) Nagle and colleagues, 18 2000
Heterogeneity: Not applicable Table 6 . Relative and absolute desirable and undesirable effects (95% confidence interval) from randomized controlled trials and certainty in the evidence for systemic antibiotics as adjuncts to definitive, conservative dental treatment compared with no systemic antibiotics as adjuncts to definitive, conservative dental treatment for pulp necrosis and symptomatic apical periodontitis and pulp necrosis and localized acute apical abscess in immunocompetent adults. 
OUTCOMES
PN-SAP or PN-LAAA
Two studies informed the effectiveness of antibiotics as adjuncts to DCDT for the following beneficial outcomes in immunocompetent adults with PN-SAP (N ¼ 41, 7-day follow-up) 17 or PN-LAAA is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. ‡ RR: Risk ratio. § For dichotomous outcomes, the guideline authors calculated absolute treatment effects via using the control group's baseline risk as the assumed control intervention risk. { RCT: Randomized controlled trial. # Henry and colleagues. 17 ** Fouad and colleagues 16 † † Serious issues of risk of bias (attrition bias and selective reporting). ‡ ‡ Serious issues of imprecision due to small sample size. § § MD: Mean difference. {{ Very serious issues of imprecision owing to small sample size and the confidence interval suggests a large benefit and a large harm. ## For included studies, the data for the outcome of pain were dichotomized (visual analog scale from 0-3) as follows: "no pain" and "mild pain" were coded as "no pain" and "moderate pain" and "severe pain" were coded as "pain." *** In Fouad and colleagues, 16 14 participants were excluded from the analysis because they either did not report their baseline swelling or they did not report swelling data at follow up. † † † In Fouad and colleauges, 16 the data for the outcome of intraoral swelling were dichotomized (visual analog scale from 0-4) as follows: "no swelling," "much less swelling," and "slightly less swelling," when compared with swelling at baseline, were coded as "no swelling." The options of "same swelling" and "more swelling," when compared with swelling at baseline, were coded as "swelling." ‡ ‡ ‡ In Henry and colleagues, 17 the data for the outcome of intraoral swelling were dichotomized (visual analog scale from 0-3) as follows: "no swelling" and "mild swelling" were coded as "no swelling" and "moderate swelling" and "severe swelling" were coded as "swelling." § § § In Fouad and colleagues, 16 15 participants were excluded from the analysis because they either did not report their baseline swelling or they did not report swelling data at follow up. ### Serious issue of imprecision owing to small sample size and the confidence interval suggests both a small benefit and a small harm. **** Owing to the total number of participants in Fouad and colleagues 16 informing this outcome, the total number of participants for the outcome of pain at 72 h was used. (N ¼ 31, 3-day follow-up). 16 We found data for all outcomes except trismus, fever, cellulitis, allergic reaction, CDI, repeat procedure, additional dental visit, or additional medical visit for this population.
Patient-reported pain intensity and experience
When given antibiotics as adjuncts to DCDT, patients may experience differences of less than one-half point on a pain VAS, ranging from 0 through 3, compared with patients who did not Fouad and colleagues, 16 1996 Henry and colleagues, 17 2001
Study or Subgroup
Total (95% CI)
Test for overall effect: z = 1.48 (P = .14) Figure 16 . Forest plot of comparison of oral systemic antibiotics versus nonuse of oral systemic antibiotics as adjuncts to definitive, conservative dental treatment in adult patients with pulp necrosis and symptomatic apical periodontitis or pulp necrosis and localized acute apical abscess for the outcome of pain intensity at 48 h. SD: Standard deviation. IV: Inverse variance. CI: Confidence interval. Fouad and colleagues, 16 1996 Henry and colleagues, 17 2001
Study or Subgroup
Total (95% CI)
Test for overall effect: z = 0.54 (P = .59) 
Events
Risk Ratio M-H, Random, 95% CI
FAVORS NO ANTIBIOTIC FAVORS ANTIBIOTIC
Fouad and colleagues, 16 1996 Henry and colleagues, 17 2001 Total events
Study or Subgroup
Total (95% CI)
Test for overall effect: z = 0.92 (P = .36) 
Events
Study or Subgroup
Total (95% CI) Figure 19 . receive antibiotics as adjuncts to DCDT over 24, 48, and 72 hours (low certainty) ( Table 6 ; Figures 15-17 ). 16, 17 Patients who received antibiotics as adjuncts to DCDT may experience a decreased risk of experiencing pain at 24 hours (20% decrease) and an increased risk of experiencing pain at 48 hours (55% increase) and 72 hours (38% increase) compared with patients who did not receive antibiotics as adjuncts to DCDT (low certainty) ( Table 6 ; Figures 18-20) . 16, 17 After 7 days, patients receiving antibiotics as adjuncts to DCDT may experience no difference in points on a VAS for pain compared with those not receiving antibiotics as adjuncts to DCDT (low certainty) ( Table 6 ; Figure 21 ). 16, 17 In addition, after 7 days, patients receiving antibiotics as adjuncts to DCDT may be 6 times more likely to experience pain than those who did not receive antibiotics as adjuncts to DCDT (low certainty) ( 
Patient-reported intraoral swelling
Patients receiving antibiotics as adjuncts to DCDT may have an increased risk of developing intraoral swelling at 24 hours (70% increase) and 48 hours (36% increase) compared with patients who did not receive antibiotics as adjuncts to DCDT. However, at 72 hours, there was no difference in intraoral swelling between the 2 groups (low to very low certainty) ( Table 6 ; Figures  23-25 ). 16, 17 After 7 days, patients receiving antibiotics as adjuncts to DCDT may have an increased risk (11% increase) of intraoral swelling compared with patients who did not receive antibiotics as adjuncts to DCDT (low certainty) (Table 6; Figure 26 ). 17 Analgesic use When given antibiotics as adjuncts to DCDT, patients may use on average 2 more 200 mg ibuprofen tablets and one-half of a 300 mg of acetaminophen with 30 mg of codeine rescue analgesic less compared with patients not receiving antibiotics as adjuncts to DCDT after 7 days (low certainty) ( Table 6 ; Figures 27-28 ). 17 Harms related to the use of systemic antibiotics (endodontic flare-up, diarrhea, and malaise) Patients receiving antibiotics as adjuncts to DCDT may have a decreased risk of experiencing an endodontic flare-up (72% decrease) and diarrhea (60% decrease) and an increased risk of reported anaphylaxis due to a penicillin drug class and received the antibiotic from a dentist; 2 patients may have reported anaphylaxis due to amoxicillin and received the antibiotic from a dentist; 6 patients may have reported anaphylaxis due to a cephalosporin drug class and received the antibiotic from a dentist; and 1 patient may have reported anaphylaxis due to cephalexin and received the antibiotic from a dentist. #, ‡ ‡, § § * Selection criteria: patient or population: any person of any age seeking treatment in any dental setting in the United States; setting: any dental setting in the United States; exposure: any systemic antibiotics; nonexposure: no systemic antibiotic. No studies meeting the selection criteria reported data on mortality due to communityassociated Clostridioides difficile infections related to a dental prescription for antibiotics; mortality due to antibiotic-resistant infections associated with a dental prescription for antibiotics; cost-effectiveness of antibiotics to treat symptomatic irreversible pulpitis with or without symptomatic apical periodontitis, pulp necrosis and symptomatic apical periodontitis, or pulp necrosis and localized acute apical abscess; admission to hospital due to community-associated C. difficile infections related to a dental prescription for antibiotics; length of hospital stay due to community-associated C. difficile infection related to a dental prescription for antibiotics;
experiencing malaise (679% increase) compared with patients not receiving antibiotics as adjuncts to DCDT over 3 days (very low certainty) ( Table 6 ; Figures 29-31 ). 16 For all outcomes, the differences were not statistically significant. For the outcomes of patientreported pain intensity and total analgesics used, the differences were also not clinically significant.
Additional Outcomes of Harm (Adverse Effects) Related to the Use of Systemic Antibiotics
For additional harm outcomes of interest not reported in the included RCTs, we extracted estimates that were as close as possible when no direct evidence was reported on a specific a priori defined outcome. We found data for all outcomes except for mortality due to community-associated CDIs related to a dental prescription for antibiotics; mortality due to antibiotic-resistant infections associated with a dental prescription for antibiotics; cost-effectiveness of antibiotics to treat SIP with or without SAP, PN-SAP or PN-LAA in any outpatient setting; admission to hospital due to community-associated CDIs related to a dental prescription for antibiotics; length of hospital stay due to community-associated CDI related to a dental prescription for antibiotics; length of hospital stay due to antibiotic-resistant infections associated with a dental prescription for antibiotics; allergic reaction and fatal anaphylaxis due to antibiotics; and allergic reaction and fatal anaphylaxis due to antibiotics associated with a dental prescription. length of hospital stay due to antibiotic-resistant infections associated with a dental prescription for antibiotics; allergic reaction due to antibiotics; allergic reaction due to antibiotics associated with a dental prescription; fatal anaphylaxis due to antibiotics; or fatal anaphylaxis due to antibiotics associated with a dental prescriptions.
† GRADE: Grading of Recommendations Assessment, Development and Evaluation. GRADE Working Group grades of evidence: high certainty: we are very confident that the true effect lies close to that of the estimate of the effect; moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. ‡ Considerations for Lessa and colleagues 30 : the case definition of C. difficile infection relying only on positive test results for C. difficile toxin or molecular assay from unformed samples sent to laboratories may lead to an underestimation of the true burden (that is, partially formed samples being untested); there is the possibility for an underestimation of "both recurrence and mortality, given that [they] assessed only first recurrences and deaths that were documented in the medical record"; there is a potential overdiagnosis or an overestimation of the burden of C. difficile infection owing to diagnostic tests being highly sensitive (that is, a poor distinction between colonization and the disease); The authors estimated the recurrence of and mortality due to C. difficile infection via using a random sample of cases that may or may not be representative of the US rates. § Considerations for Chitnis and colleagues 27 : there are potential issues of generalizability to the US population given that patients included in the analysis with community-associated C. difficile infection were more likely to be white and female; only a convenience sample of stools were sent for definitive testing (40%); although antibiotic use within 12 weeks was adjudicated on the basis of a telephone interview (self-reported) and medical records, it is unclear as to how many cases were confirmed using both methods; hospitalization in which C. difficile infection was the primary reason for admission was ascertained through medical records. { Upgraded due to a large effect on the basis of observational studies without important risk of bias or other limitations. # This is likely an overestimation of the effect of dental prescriptions for antibiotics because the provided information and data did not differentiate between inpatient and outpatient antibiotic prescriptions. The guideline authors assume that prescribing for dental conditions rarely occurs in inpatient settings. ** Considerations for Hicks and colleagues 26 : dentistry accounts for 10% of the total outpatient antibiotic prescriptions in the United States; the magnitude of antibiotic prescriptions may not necessarily represent the magnitude of antibiotic consumption by patients; there is possible underestimation owing to the total number of prescriptions from other nondental professionals (for example, emergency medicine services) for any dental condition not being included in the estimate; estimates related to antibiotic prescribing practices reported by Hicks and colleagues 26 correspond to that of general dentists and dental specialties combined. † † Downgraded owing to serious issues of indirectness related to estimates being extrapolated to illustrate the burden in a dental setting. ‡ ‡ Data were adjusted considering that dentistry accounts for 10% of total outpatient antibiotic prescriptions in the United States. § § The presented estimate assumes that dental prescriptions for any antibiotic has the same potential of inducing antibiotic resistance as nondental related prescriptions. {{ Considerations for Centers for Disease Control and Prevention 3 : no reports containing methods or results are linked to this report; estimates used from this report are likely an underestimation of the true burden of antibiotic resistance related outcomes; the magnitude of antibiotic resistance related outcomes may not necessarily represent the magnitude of antibiotics prescribed for and consumed by patients. ## Considerations for Zhang and colleagues 32 : all included studies in the review reported direct medical costs from a hospital perspective; indirect costs to patients and society and costs of additional care after hospital discharge have not been captured (for example, productivity loss due to work day losses and costs in long-term care facilities). Approximately 9% of patients with C. difficile infections were discharged to a long-term care facility for an average of 24 d of after-care, which would result in an additional $141 million burden on the health care system and society due to longterm care facility transfers; primary C. difficile infections were not separated for the estimation of recurrent C. difficile infection costs; there was discrepancy in case definitions in cost studies versus surveillance and epidemiological studies (for example, community-versus health careÀassociated C. difficile infections); the total costs of C. difficile infection in the United States may be higher than the reported estimate. *** This is likely an overestimation of the effect of dental prescriptions for antibiotics owing to the primary study not measuring or reporting antibiotic exposure. † † † Considerations for Mainous and colleagues 31 : the methods did not allow the guideline authors to determine whether the infection arose in the hospital or the patients were colonized or infected before admission; International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes were used instead of laboratory results on bacterial cultures; "Greater awareness of drug resistance among hospital coding departments may have prompted more attention to adding these codes to discharge records of patients who were relatively healthy and discharged without incident." ‡ ‡ ‡ Considerations for Johnston and colleagues 29 : International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes were used instead of laboratory results on bacterial cultures; the authors were unable to distinguish between hospital-acquired and communityacquired infections; 10% of the eligible population was excluded due to missing data. § § § Considerations for Dhopeshwarkar and colleagues 28 : the estimates presented in this study only included penicillin and cephalosporin drug classes and amoxicillin and cephalexin drugs and did not include other individual drugs commonly prescribed by dentists such as clindamycin. Considerations for: Durkin and colleagues: 6 there may be issues of generalizability as only patients from 2 Boston-area hospitals were included in this analysis, which may not be representative of inpatient populations admitted to other US hospitals; there was a potential overestimate of the occurrence of anaphylaxis owing to reported cases not being confirmed by tryptase tests; there was possible underestimation owing to exclusion of codes listed in electronic health records not directly linking to anaphylaxis; there was uncertainty surrounding whether the estimates of the reported or observed cases of anaphylaxis resulted in death. 
Very low ‡ ‡
The guideline authors approximated that 6.4% of people with community-associated C. difficile infections who were exposed to antibiotics received the prescription from a dentist. This represents 10,221 cases of 159,700 total C. difficile infections in 2011 (95% CI, 8,506 to 11, 904 Community-associated C. difficile infections Data suggest that approximately 6,400 cases of 10,000 total cases of community-associated CDI may be associated with an exposure to antibiotics (moderate certainty). 27, 30 From a dental perspective, this translates into an estimated 640 cases of community-associated CDIs of 10,000 total community-associated CDI cases that may be associated with patients consuming antibiotics received from a dentist (very low certainty). 26, 27, 30 Furthermore, of 10,000 total cases of community-associated CDIs, approximately 80 people died after a possible exposure to antibiotics (moderate certainty) ( Tables 7-8) . 27, 30 Antibiotic-resistant infections Annually, 2 million people may be affected by antibiotic-resistant infections in the United States, and there are approximately 23,000 deaths due to these infections (low certainty) (Tables 7-8). 11 
Costs
In 2008, $20 billion in direct costs may have been attributable to antibiotic-resistant infections and an additional $35 billion in associated productivity losses (low certainty). 11 This translates into an * Selection criteria: patient or population: any person of any age seeking treatment in any dental setting in the United States; setting: any dental setting in the United States; exposure: any systemic antibiotics; nonexposure: no systemic antibiotic. No studies meeting the selection criteria reported data on mortality due to communityassociated Clostridioides difficile infections related to a dental prescription for antibiotics, length of hospital stay due to community-associated C. difficile infection related to a dental prescription for antibiotics, length of hospital stay due to antibiotic-resistant infections associated with a dental prescription for antibiotics, allergic reaction due to antibiotics, allergic reaction due to antibiotics associated with a dental prescription, fatal anaphylaxis due to antibiotics, or fatal anaphylaxis due to antibiotics associated with a dental prescriptions. † GRADE: Grading of Recommendations Assessment, Development and Evaluation. GRADE Working Group grades of evidence: high certainty: we are very confident that the true effect lies close to that of the estimate of the effect; moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. ‡ Considerations for Lessa and colleagues 30 : the case definition of C. difficile infection relying only on positive test results for C. difficile toxin or molecular assay from unformed samples sent to laboratories may lead to an underestimation of the true burden (that is, partially formed samples being untested); there is the possibility for an underestimation of "both recurrence and mortality, given that [they] assessed only first recurrences and deaths that were documented in the medical record"; there is a potential over-diagnosis or an overestimation of the burden of C. difficile infection owing to diagnostic tests being highly sensitive (that is, a poor distinction between colonization and the disease); the authors estimated the recurrence of and mortality due to C. difficile infection via using a random sample of cases that may or may not be representative of the US rates. § Considerations for Chitnis and colleagues 27 : there are potential issues of generalizability to the US population given that patients included in the analysis with community-associated C. difficile infection were more likely to be white and female; only a convenience sample of stools were sent for definitive testing (40%); although antibiotic use within 12 weeks was adjudicated on the basis of a telephone interview (self-reported) and medical records, it is unclear as to how many cases were confirmed using both methods; hospitalization in which C. difficile infection was the primary reason for admission was ascertained through medical records.
{ Upgraded due to a large effect based on observational studies without important risk of bias or other limitations. # CI: Confidence interval. ** This is likely an overestimation of the effect of dental prescriptions for antibiotics because the provided information and data did not differentiate between inpatient and outpatient antibiotic prescriptions. The guideline authors assume that prescribing for dental conditions rarely occurs in inpatient settings. † † Considerations for Hicks and colleagues 26 : dentistry accounts for 10% of the total outpatient antibiotic prescriptions in the United States; the magnitude of antibiotic prescriptions may not necessarily represent the magnitude of antibiotic consumption by patients; there is possible underestimation owing to the total number of prescriptions from other nondental professionals (for example, emergency medicine services) for any dental condition not being included in the estimate; estimates related to antibiotic prescribing practices reported by Hicks and colleagues 26 correspond to that of general dentists and not all dental specialties combined. ‡ ‡ Downgraded owing to serious issues of indirectness related to estimates being extrapolated to illustrate the burden in a dental setting. § § Data were adjusted considering that dentistry accounts for 10% of total outpatient antibiotic prescriptions in the United States. {{ The presented estimate assumes that dental prescriptions for any antibiotic has the same potential of inducing antibiotic resistance as nondental related prescriptions. ## Considerations for Centers for Disease Control and Prevention 3 : no reports containing methods or results is linked to this report; estimates used from this report are likely an underestimation of the true burden of antibiotic resistance related outcomes; the magnitude of antibiotic resistance related outcomes may not necessarily represent the magnitude of antibiotics prescribed for and consumed by patients. *** Considerations for Zhang and colleagues 32 : all included studies in the Zhang and colleagues review reported direct medical costs from a hospital perspective; indirect costs to patients and society and costs of additional care after hospital discharge were not captured (for example, productivity loss due to work day losses and costs in long-term care facilities). Approximately 9% of patients with C. difficile infections were discharged to a long-term care facility for an average of 24 d of after-care, which would result in an additional $141 million burden on the health care system and society due to long-term care facility transfers; primary C. difficile infections were not separated for the estimation of recurrent C. difficile infection costs; there was discrepancy in case definitions in cost studies versus surveillance and epidemiologic studies (for example, community-versus health careÀassociated C. difficile infections); the total costs of C. difficile infection in the United States may be higher than the reported estimate. † † † This is likely an overestimation of the effect of dental prescriptions for antibiotics owing to the primary study not measuring or reporting antibiotic exposure. ‡ ‡ ‡ Considerations for Mainous and colleagues 31 : the methods did not allow the guideline authors to determine whether the infection arose in the hospital or if patients were colonized or infected prior to admission, International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes were used instead of laboratory results on bacterial cultures; "Greater awareness of drug resistance among hospital coding departments may have prompted more attention to adding these codes to discharge records of patients who were relatively healthy and discharged without incident." § § § Considerations for Johnston and colleagues: International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes were used instead of laboratory results on bacterial cultures; the authors were unable to distinguish between hospital-acquired and community-acquired infections; 10% of the eligible population was excluded owing to missing data. {{{ Considerations for Dhopeshwarkar and colleagues 28 : the estimates presented in this study only included penicillin and cephalosporin drug classes and amoxicillin and cephalexin drugs and did not include other individual drugs commonly prescribed by dentists such as clindamycin. Source: Durkin and colleagues; 6 there may be issues of generalizability as only patients from 2 Boston-area hospitals were included in this analysis, which may not be representative of inpatient populations admitted to other US hospitals; there was a potential overestimate of the occurrence of anaphylaxis owing to reported cases not being confirmed by tryptase tests; there was possible underestimation owing to exclusion of codes listed in electronic health records not directly linking to anaphylaxis; there was uncertainty surrounding whether the estimates of the reported or observed cases of anaphylaxis resulted in death.
estimated $2 billion in direct costs and $3.5 billion in productivity loss associated with dental prescriptions for antibiotics (very low certainty). 11, 26 In 2015, community-associated CDIs were associated with approximately $3 billion in costs (moderate certainty), 30, 32, 33 which may translate into approximately $300 million in costs being associated with a dental prescription for antibiotics (very low certainty) ( Tables 7-8) . 26, 30, 32 Hospitalizations Of 10,000 people with community-associated CDIs, 1,270 may have been admitted to a hospital with community-associated CDI as the primary reason for admission (moderate certainty). 27, 30 In 2006, 2.4% of all infection-related hospitalizations could be attributed to antibiotic-resistant infections (low certainty). 31 This translates into approximately 0.24% of infection-related hospitalizations due to antibiotic resistance being associated with dental prescriptions for antibiotics (very low certainty). 26, 31 In addition, evidence suggests patients were hospitalized on average for 5.7 days owing to community-associated CDIs 32 and approximately 9 days for bacterial infections associated with multidrug-resistant microorganisms (low certainty) (Tables 7-8). 29 
Anaphylaxis
Evidence suggests that from 1995 through 2013, for every 10,000 hospitalizations, about 46 were attributed to anaphylaxis associated with the use of a penicillin drug class and another 6 anaphylaxisrelated hospitalizations were associated with a cephalosporin drug class (low certainty). 34 From a dental perspective, this is approximately 46 and 6 of 100,000 hospitalizations due to a penicillin or cephalosporin drug class prescribed from a dentist, respectively (very low certainty) ( Tables 7-8 ). 26, 28 16 and Henry and colleagues. 17 † In dichotomizing the outcome of intraoral swelling, option 1 categorized "no swelling" and "mild swelling" used in Henry and colleagues 17 and "no swelling," "much less swelling," and "slightly less swelling" used in Fouad and colleagues 16 as "no swelling." "Moderate swelling" and "severe swelling" used in Henry and colleagues 17 and "same swelling" and "more swelling" used in Fouad and colleagues 16 were categorized as "swelling." ‡ In dichotomizing the outcome of intraoral swelling, option 2 categorized "no swelling" and "mild swelling" used in Henry and colleagues 17 and "no swelling" and "much less swelling" used in Fouad and colleagues 16 as "no swelling." "Moderate swelling" and "severe swelling" used in Henry and colleagues 17 and "slightly less swelling," "same swelling," and "more swelling" used in Fouad and colleagues 16 were categorized as "swelling."
DISCUSSION
Summary of the main results
Evidence on the effect of antibiotics versus no antibiotics, with or without DCDT, for outcomes of pain and intraoral swelling showed both a small to large benefit and a small to large harm. Data on outcomes of endodontic flare-up, diarrhea, and malaise suggest that there may be a reduced risk of experiencing an endodontic flare-up and diarrhea and an increased risk of experiencing malaise associated with the use of antibiotics as adjuncts to DCDT. [16] [17] [18] Evidence suggests a large magnitude of effect for additional harm outcomes such as CDI, mortality, and hospitalization associated with the use of antibiotics for any condition, medical or dental. 11, [26] [27] [28] [29] [30] [31] [32] Certainty in the evidence The certainty in the evidence ranged from very low to low across all outcomes informed by RCT data and from very low to moderate for all harm outcomes informed by observational data. We downgraded the certainty for RCT data owing to issues of risk of bias (attrition bias and selective reporting), imprecision (confidence intervals showing both a large benefit and a large harm), and failure to meet the optimal information size. We upgraded additional data collected from observational reports on harm outcomes owing to a potentially large magnitude of effect.
Comparison with other reviews Although our review is partially an update of 2 preexisting Cochrane reviews, 13,14 a 2016 review assessed the effects of antibiotics to treat endodontic infections and pain. 35 Unlike the Cochrane reviews 13, 14 and our updated review, in the 2016 review the study authors included patients with pulp necrosis and asymptomatic apical periodontitis along with symptomatic patients. Two 2003 systematic reviews assessed the effects of antibiotics for the management of PN-SAP and PN-LAAA in adult patients. 36, 37 Unlike the Cochrane reviews 13, 14 and our updated review, these reviews included trials that provided head-to-head comparisons of antibiotics with other antibiotics and other management options, included extractions as a dental treatment of interest, and did not use GRADE to assess certainty in the evidence. Similar to our review, these 4 previously published reviews evaluated local and systemic symptom relief in patients with pulpal and periapical conditions, and their estimates also suggest that antibiotics are associated with both benefits and harms. 13, 14, 36, 37 Unlike our review, none of these reviews included additional harm outcomes informed by observational data. 13, 14, 36, 37 In addition, the 2014 review by Cope and colleagues 13 and the 2016 review by Agnihotry and colleagues 14 were updated and published concurrently by the Cochrane Collaboration in 2018 38 and 2019, 39 respectively, during our update process, and the authors did not find any new eligible studies to be included in their reviews. Other reviews have summarized harms associated with antibiotic use, but their patient populations were too narrow (for example, urinary tract infection patients) for us to use these reviews to inform our outcomes. 40 
Strengths and limitations of this review
The strengths of our review include that we used methodology in line with recommendations from the Cochrane Handbook for Systematic Reviews of Interventions 24 and that we screened and performed data abstraction independently and in duplicate, contacted authors for data clarification, and assessed the certainty in the evidence using GRADE. A major limitation of this review is the lack of accurate estimates quantifying the direct impact of dental antibiotic prescribing on health outcomes. Although we attempted to provide an estimation of this impact via attributing 10% of the magnitude of harm outcomes to dental prescriptions (on the basis of reports approximating that 10% of all antibiotic prescriptions are made by dentists), 8, 41 this exercise has a number of limitations. It assumes that for all antibiotic prescriptions made by medical and oral health care professionals, all antibiotic types may contribute equally to outcomes (such as antibiotic resistance), disregards the duration of antibiotic regimens, and does not account for antibiotic prescribing versus consumption (that is, even if an antibiotic is prescribed, the amount consumed by a patient is not measured in relation to the measured outcome). These adjusted estimates may reflect the impact of antibiotics used for any dental indication and are not limited to the conditions of interest in this review. Additional limitations of our review include a paucity of large, robustly designed trials in this subject area, inclusion of studies with poorly defined conditions of interest, and inconsistencies between target conditions and patient signs and symptoms in the primary trials.
CONCLUSIONS
Evidence on the effects of antibiotics, either alone or as adjuncts to DCDT, suggests both a benefit and a harm for the outcomes of pain and intraoral swelling. Evidence also suggests large potential harms associated with antibiotic use for any condition for the outcomes of community-associated CDI, mortality due to community-associated CDI, antibiotic-resistant infections, and mortality due to antibiotic-resistant infections. Clinical decision making should include this summary of benefits and harms along with other pertinent considerations, including the patient's values and preferences, acceptability, and feasibility. We conducted this review in collaboration with an expert panel during the development of an associated clinical practice guideline. 12 For Cochrane Reviews licensed under the standard Cochrane license for publication, the Cochrane Collaboration grants each user a nonexclusive, nontransferable, perpetual, royalty-free, worldwide license for noncommercial use of the data. Users may extract, download, and make copies of the information contained in the data and may share that information with third parties. Users must present the data accurately and in a manner that is not misleading to others.
APPENDIX METHODS
Selection criteria
A complete list of outcomes for total analgesics used includes the total number of nonsteroidal antiinflammatory drugs used and the total number of rescue analgesics used. A complete list of outcomes for progression of disease to a more severe state includes malaise, trismus, fever, cellulitis, additional dental visit, and additional medical visit.
A complete list of outcomes for community-associated Clostridioides difficile infection (CDI) includes community-associated CDI, community-associated CDI related to a dental prescription for antibiotics, and mortality due to community-associated CDI.
A complete list of outcomes for antibiotic-resistant infections includes antibiotic-resistant infections and mortality due to antibiotic-resistant infections.
A complete list of outcomes for costs includes community-associated CDI related costs; community-associated CDI related costs associated with a dental prescription for antibiotics; antibiotic-resistant infections related costs; antibiotic-resistant infections related costs associated with a dental prescriptions for antibiotics; and cost-effectiveness of antibiotics to treat symptomatic irreversible pulpitis with or without symptomatic apical periodontitis, pulp necrosis and symptomatic apical periodontitis, or pulp necrosis and localized acute apical.
A complete list of outcomes of hospitalizations includes admission to hospital due to community associated CDI, admission to hospital due to community-associated CDI related to a dental prescription for antibiotics, admission to hospital due to antibiotic-resistant infection, admission to hospital due to antibiotic-resistant infection associated with dental prescriptions for antibiotics, length of hospital stay due to community-associated CDI, length of hospital stay due to communityassociated CDI related to a dental prescription for antibiotics, length of hospital stay due to antibiotic-resistant infection, and length of hospital stay due to antibiotic-resistant infections associated with a dental prescription for antibiotics.
A complete list of outcomes of anaphylaxis includes allergic reaction to antibiotics, allergic reaction to antibiotics associated with a dental prescription, anaphylaxis due to antibiotics, anaphylaxis due to antibiotics associated with a dental prescription, fatal anaphylaxis due to antibiotics, and fatal anaphylaxis due to antibiotics associated with a dental prescription.
Literature Search
Search Strategy #1 (Update of Cope 2014). Search conducted in this database on June 5, 2018. Embase. Database: Embase via embase.com #1 'antiinfective agent'/exp #2 'penicillin derivative'/exp #3 antibiotic* OR 'anti-biotic*' OR 'anti biotic*' #4 antibacterial* OR 'anti-bacterial*' OR 'anti bacterial*' #5 antiinfect* OR 'anti-infect*' OR 'anti infect*' #6 antimicrobial* OR 'anti-microbial*' OR 'anti microbial*' #7 penicillin* OR amox?cillin OR ampicillin OR erythromycin OR clindamycin* OR doxycy- #15 (tooth OR teeth) NEXT/5 absces* #16 (periapical NEXT/5 absces*) OR ('peri-apical' NEXT/5 absces*) OR (apical NEXT/5 absces*) #17 (periapical NEXT/5 periodont*) OR ('peri-apical' NEXT/5 periodont*) OR (apical NEXT/5 periodont*) #18 (periapical NEXT/5 inflam*) OR ('peri-apical' NEXT/5 inflam*) OR (apical NEXT/5 inflam*) #19 (periapical NEXT/5 infect*) OR ('peri-apical' NEXT/5 infect*) OR (apical NEXT/5 infect*) #20 (dentoalveol* NEXT/5 absces*) OR ('dento-alveol*' NEXT/5 absces*) OR (alveol* NEXT/5 absces*) #21 (periradicular NEXT/5 absces*) OR ('peri-radicular' NEXT/5 absces*) OR (radicular NEXT/5 absces*) #22 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 #23 #12 AND #22 #24 random* #25 factorial* #26 (crossover* OR cross) AND over* OR 'cross over*' #27 placebo #28 doubl* NEXT/1 blind* #29 singl* NEXT/1 blind* #30 assign* #31 allocat* #32 volunteer* #33 'crossover procedure'/exp #34 'double blind procedure'/exp #35 'randomized controlled trial'/exp #36 'single blind procedure'/exp #37 #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR Embase. Database: Embase via embase.com #1 'antiinfective agent'/exp #2 'penicillin derivative'/exp #3 antibiotic* OR 'anti-biotic*' OR 'anti biotic*' #4 antibacterial* OR 'anti-bacterial*' OR 'anti bacterial*' #5 antiinfect* OR 'anti-infect*' OR 'anti infect*' #6 antimicrobial* OR 'anti-microbial*' OR 'anti microbial*' #7 penicillin* OR amox?cillin OR ampicillin OR erythromycin OR clindamycin* OR doxycy- #3 #1 OR #2 #4 'meta analysis'/exp #5 (meta NEXT/1 analy*) OR metaanalys* #6 systematic NEXT/1 (review*1 OR overview*1) #7 #4 OR #5 OR #6 #8 cancerlit:ab #9 cochrane:ab #10 embase:ab #11 psychlit:ab OR psyclit:ab #12 psychinfo:ab OR psycinfo:ab #13 cinahl:ab OR cinhal:ab #14 'science citation index':ab #15 bids:ab #16 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 #17 'reference lists':ab #18 bibliograph*:ab #19 'hand-search*':ab #20 'manual search*':ab #21 'relevant journals':ab #22 #17 OR #18 OR #19 OR #20 OR #21 #23 'data extraction':ab #24 'selection criteria':ab #25 #23 OR #24 #26 'review':it #27 #25 AND #26 #28 letter:it #29 editorial:it #30 'animal'/exp #31 'human'/exp #32 #30 NOT (#30 AND #31) #33 #28 OR #29 OR #32 #34 #7 OR #16 OR #22 OR #27 #35 #34 NOT #33 #36 #3 AND #35 #37 'child'/exp #38 'adult'/exp #39 #36 NOT (#37 NOT #38) #40 #39 AND (2013:py OR 2014:py OR 2015:py OR 2016:py OR 2017:py OR 2018:py)
Selection of primary studies and data extraction
We conducted a sensitivity analysis for 1 3-arm study 16 (arm 1: antibiotics, arm 2: placebo, arm 3: no medication) to determine if it was appropriate to combine arms 2 and 3 owing to similarities in their clinical mechanism. In comparing the treatment effect of arm 1 versus arm 2 and arm 2 versus arm 3, the confidence intervals overlapped substantially. Therefore, we deemed it acceptable to combine the placebo and no medication arms into a single "no antibiotics" arm. Combining these arms allowed us to increase the power and precision in our pooled estimates (Table 9 ). 16, 17 Outcome measures Included studies informing pain outcomes used the same 0 to 3 visual analog scale (VAS), in which 0 is "no pain," 1 is "mild pain," 2 is "moderate pain," and 3 is "severe pain." [16] [17] [18] Dichotomous results for pain experience were categorized as follows: 0 and 1 are "no pain," and 2 and 3 are "pain."
Included studies informing the outcome of intraoral swelling used 2 different VASs. One study used a VAS ranging from 0 to 3, in which 0 is no swelling, 1 is mild swelling, 2 is moderate swelling, and 3 is severe swelling. 17 Another study used a VAS ranging from 0 to 4 that asked patients to compare their current swelling with preoperative swelling, in which 0 is no swelling, 1 is much less swelling, 2 is slightly less swelling, 3 is same swelling, and 4 is more swelling. 16 We conducted a sensitivity analysis to determine the threshold to dichotomize this outcome. In dichotomizing the outcome of intraoral swelling for Henry and colleagues, 17 0 and 1 were categorized as "no swelling," and 2 and 3 were categorized as "swelling." Because the 0 to 4 VAS used in Fouad and colleagues 16 contained 5 possible choices, there were 2 options to dichotomize this scale. Option 1 categorized 0, 1, and 2 as "no swelling" and 3 and 4 as "swelling." Option 2 categorized 0 and 1 as "no swelling" and 2, 3, and 4 as "swelling." When the treatment effect of these 2 options, along with the dichotomized data from Henry and colleagues, 17 were compared, the confidence intervals overlapped substantially ( Table 9 ), indicating that the results would be similar irrespective of the threshold chosen. In presenting these choices to the expert panel, methodologists communicated that option 1 indicated that even a small reduction in swelling would be relevant to the patient and that option 2 meant that although this might represent a small change in swelling, it is likely not important to patient. By majority vote, the decision was made to use option 1 for data analysis for the outcome of intraoral swelling.
For dichotomous outcomes (for example, pain experience and intraoral swelling), we interpreted a relative risk above 1 as having not favored antibiotics, whereas we interpreted a relative risk below 1 as favoring antibiotics. For continuous outcomes (for example, pain intensity), we interpreted a positive mean difference as the average increase in an outcome.
Assessment of risk of bias and methodological quality
Two reviewers (M.P.T., O.U.) independently assessed the risk of bias of the included studies informing beneficial outcomes using the Cochrane Risk of Bias tool (Review Manager, Version 5.3, Cochrane Collaboration) for the domains of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. Judgments that were assigned to each study were either low, high, or unclear risk of bias. Two reviewers (L.P., M.P.T.) independently assessed the risk of bias of included studies informing harm outcomes using a tool developed by Hoy and colleagues. 19 This 10-item tool assessed the internal and external validity of prevalence studies. Responses to each question can be yes, no, or not reported. Reviewers also independently assessed the quality of systematic reviews informing harm outcomes using the AMSTAR 2 critical appraisal tool. 20 Any disagreements in judgments were resolved by a third reviewer (A.C.-L.).
Certainty in the evidence
We assessed the certainty in the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach across studies at an outcome level. 21 The certainty in the evidence can either be high, moderate, low, or very low. In GRADE, RCTs start as high certainty in the evidence, whereas observational studies start as low certainty in the evidence. Certainty can be reduced when serious or very serious issues of risk of bias, inconsistency, indirectness, imprecision, and publication bias are identified. We assessed inconsistency using the c 2 test and I 2 statistic and via visual assessment of forest plots. We assessed indirectness via considering to what extent each included study's population, interventions, comparators, and outcomes differed from our clinical questions. We assessed imprecision via n evaluating the width of confidence intervals (appreciable benefit or harm) and using the optimal information size for both dichotomous and continuous outcomes; n for dichotomous outcomes, considering 10% reduction or increase in pain experience or intraoral swelling as clinically significant; n for continuous outcomes, considering a 1 point change in pain intensity and a 6 pill change in total number of analgesics as clinically significant.
We planned to evaluate publication bias by means of using a funnel plot when 10 or more studies were available. Certainty in the evidence can be upgraded when a large magnitude of effect, opposing plausible residual bias or confounding that reduces a treatment effect, or dose-response gradient is observed. 
